Member Info for Saxondale

New Faron presentation on Redeye ( thanks Tom on twitter for spotting it )

Markku on great form - very positive and confident .
New slides - bringing latest data and expectations.

Suggests that Bex acquisition would give Faron an Mcap of EUR2-5 billion given th growing market and efficacy potential .

Anti PD1 market $36 billion this year , expected to be nearly $100 billion in next 6-7 years .
Huge growth showing how important this sector is , and this is with the vast majority of patients not even responding .

BEXCOMBO - they have selected 3 potential cohorts that look most promising - Head and Neck /Urethral/Lung
BEXMAB - as expected he is super excited here - more detail on first responder - showing great signs of improvement.
More data results coming in next few weeks and months . Open study . Very confident .
New slides giving more detail on trial dosing and escalation also.

Traumakine - not to be covered today - but he said that they are pushing for it to be a clinical product and would talk later.

https://www.redeye.se/video/company-prerecorded-presentation/864997/faron-pharmaceuticals?searchResult=851e838b-e0bc-3ce8-93ed-a993eddb15fb&query=&fromPage=SAVED

Today was a top up and average down day .
Picking up chunks under 7.5 was very satisfying .
Hit my target number of shares a few months ago , but when you see the SP this low , you just have to dig down the sofa .
Good luck all and keep up the good work .

Nice one .
They obviously see the value and importance of this discovery .
Most in that area only got EUR4000 , only 3 above EUR100,000
Hollmen lab second largest grant ( for 2 yrs research)
Highest one at EUR180,000 was for 3 years .

sorry can't seem to spell today ( fingers a bit cold )

Also an event tomoorow at the Christie hospital in Manchester ( one of our 3 UK trial sites for Bex)

'Precision medicine in Oncology'

A talk about new targeted oncology trials that are underway .
"The Experimental Cancer Medicine Team (ECMT) at The Christie are at the frontier of novel treatments, including cellular therapies."

https://www.christie.nhs.uk/education/continuing-professional-development/study-days-and-conferences/precision-medicine-in-oncology

We seem to share a number of trial sites in the UK with Avacata - also pursuing a novel treatment ( delivery system) for cancer .
Fair to say - both companies are at the premium locations for their research , with the right kinds of people taking notice .

https://www.youtube.com/watch?v=bCgaF7FY9mo&t=28s

Focusing on the pressures that allow cancer cells to become resistant to treatment .

Lets hope Jonathan Knowles has her number .

This news was yesterday ( 22nd Nov)
From ICR own website - a more detailed write up of what they are doing at the Royal Marsden .
https://www.icr.ac.uk/news-archive/scientists-plot-extinction-of-cancers-by-disrupting-their-ecosystems
From that page clock this paragraph !

“Immunotherapy has begun to revolutionise treatment for some cancer patients – we’re even starting to see cures in people with advanced disease who, until recently, were destined to die of their cancers. But unfortunately, immunotherapy doesn’t work for all patients or all cancer types, and we need to do much better both at predicting whether it will work, and increasing the effectiveness of treatment. 

“We believe that there are huge opportunities to use combinations of immunotherapy and other treatments like radiotherapy to disrupt cancer’s ecosystem. We are aiming to tilt the balance in favour of the immune system and make the environment inhospitable to cancer cells and favourable for elements of the immune system that can attack them, so that we can make the disease extinct within the body. We’re even using viruses to accurately target cancer cells and draw a powerful immune response to them. We think the reward will be immunotherapy that works for many more patients, and that increasingly gives even those with advanced cancer the hope of a cure.”

Markku could have written that himself lol .

There can't be that many novel cancer immunotherapy drugs being trialed at the Royal Marsden that are saving lives in people with advanced cancer who would otherwise die .
We are one of them - and are publishing this sort of data

· 100% overall survival at 12-months in PD-1 blockade refractory melanoma patients who experienced clinical benefit from bexmarilimab

· Patients with cold tumors, defined by low baseline levels of pro-inflammatory cytokines, were more likely to experience clinical benefit following treatment with bexmarilimab

· Patients who experienced clinical benefit from bexmarilimab had a seven-fold increase in serum interferon gamma (IFN?), suggesting retreatment with anti-PD-1 could be beneficial

News item -
The Institute of Cancer Research (ICR) says it has launched a "really exciting" five-year research strategy which hopes to "unravel and disrupt cancer's ecosystems".

The Royal Marsden is one of Farons trial sites for Matins - so they are fully aware of Bexmarilimab .

Interesting for them to come out with this kind of statement -

ICR and Royal Marsden scientists believe they can make significant progress in areas such as destroying cancer cells, boosting the body's power to fight the disease, and stopping healthy cells cell being tricked into helping cancer survive.

That is pretty much Bexmarilimab in a nutshell .

"Dr Olivia Rossanese, director of drug discovery at the ICR, said more personalised treatments are already helping people live for longer, but that some forms of the disease remain very difficult to treat."

"We plan to open up completely new lines of attack against cancer, so we can overcome cancer's deadly ability to evolve and become resistant to treatment," she said.

"We want to discover better targets within tumours and the wider ecosystem that we can attack with drugs.

"We're finding powerful new ways to eradicate cancer proteins completely and discovering smarter combination treatments that attack cancer on multiple fronts.

Would be wonderful if Bex could be part of this .

https://news.sky.com/story/advanced-cancer-survival-rates-could-double-within-a-decade-say-scientists-12752775

Back above break even again at last .
Nice to see some interest .
Not long to wait now until possible fireworks

Got my extra cheap shares in the end . Thanks whoever orchestrated that .

We are due news on a few fronts .
This little re arrangement with IPF is just one front .
FDA meeting details
Traumakine
Bexmab data
Future Funding Partner

Just sitting tight - I have a feeling Fridays RNS was just the start of a run of news that will be coming down the pipe.

Thanks .
Minimal effect to shareholders , and they note that the other details relating to changes have not been made public .

Based on the available information, changing the loan terms seems to have a marginal negative effect on shareholders as the subscription price decreases. The reason for changing the loan terms remains unclear from the announcement. The subscriptions of new shares related to the warrants will moderately increase the number of Faron's shares, and in our estimation, their importance for the shareholders is minor. We expect news about financing solutions from Faron in the near future, as the company has stated that the current financing is sufficient until Q1'23.

Normally Faron are pretty good with contracts ( remember they won EUR3.8m in a claim against Rentschler)
For them to rearrange matters to give IPF an extra EUR300k odd on their warrants suggests they either dropped a clanger in the original contract , or something has been rejigged to also help Faron.

IPF have funded Faron with EUR10m so far .

The next tranches of EUR20m are based on Faron raising EUR15m ( so far EUR13m)
Has funding until March 2023 ( this I believe would be the case)
Also gaining FDA Pivotal trial approval (happening as we speak)

So why rearrange ?

Would IPF be wanting cheaper warrants / perhaps in exchange for reducing their interest charge / settlement fees on the EUR10m ?
If in a perfect scenario - what about if IPF were made aware that Faron will be doing a Partner deal , and won't be needing their extra EUR20m . Perhaps there is an early settlement fee , or even no early payment clause . Faron have agreed to reduce warrant price to clear the way forward .
IPF must have given something to get their warrants discounted by about 40%.

Or it may just be a total clanger where some small print in that agreement allowed them to reprice warrants if there was a lower priced placing .

I guess we find out eventually .

I think you may have only heard half the story Drac .
This re- arrangement has been done based on authorisation granted at the EGM in July .

From that RNS -
The Authorisation shall be used for material arrangements from the Company's point of view, such as financing (including, without limitation, issuance of warrants under the funding agreement with IPF Partners announced on February 28, 2022) or implementing business arrangements, investments or for other such purposes determined by the Board where a weighty financial reason for issuing shares, options or other special rights entitling to shares, and possibly deviating from the shareholders' pre-emptive rights, exists.

So , for them to do this , there has to be a 'weighty financial reason ' .

I might be wrong , but I don't think think this is a case of them just bending over for IPF .

Something has been re-arranged . Whatever was agreed with IPF originally has mutually been amended .

We are always the last to hear about financials ( eg placings etc) , and just see the SP slide prior to such dilutions etc .

This time the SP has gone up . It may be coincidence , but at worst I see this as some kind of refinace arrangement for perhaps different terms in exchange for lower priced warrants , or at best part of some future funding plan that recent events have required .

I think this may be part 1 of a 2 part bit of news .

Always the optimist

RNS renegotiating the IPF warrants price and a few details regarding the following tranches if needed .

The amendment of the Warrant terms and conditions has been resolved as a result of the Company and IPF entering into an amendment and restatement agreement dated November 18, 2022 which also amends certain covenant, margin and fee structure provisions of the Funding Agreement.

So looks like IPF have got themselves some cheaper warrants on this first tranche (319,000 of them ) .
Equivalent to the latest placing at 1.85 euro - or lower if their is a lower placing ( unlikely I'd say)
Rather than the original 3 euro price.
So they just got a £300k discount ( if they use them )
Nice for them .
I wonder what got renegotiated to scratch Farons back ?
Surely you can't just ask for backdated cheaper warrants just because they last placing was at a lower price ?
Unless it was part of the original deal ?
Oh well , at least it means that future IPF EUR20m funding is still on the cards should they need it .

Whoever it was , they may have finished now , or are taking a break .
Either way , the importance was getting the shares pronto , despite knowing it would shift price up .
That indicates confidence that some important news is soon to be released , and that paying a premium wasn't an issue , given that we are so undervalued anyway .
Only 4 or so weeks left of this quarter , including Thanks Giving week .
One would hope that perhaps the FDA meeting has already taken place , and they are now bashing out the nuts and bolts of the next phases .

Exactly .
NCYT boomed on a massive order - but it took a few days to sink in . Unfortunately we know how it ended , but thats not this scenario.
EUA boomed too purely on hype and speculation ( and I did very well ) . But again it popped on unrealised sale ( and war obviously)
ARB ( i rode that for a bit but got burnt at the end ) - can't even find words to make sense of that one lol

But with HARL , we've been given the news in black and white - no speculation or hype needed , in as much the order is in the bag - with plenty more in the pipeline , and investment in infrastructure that will set this company up for decades to come .

I wonder how many people , like me , had to speed research HARL yesterday .
Amazing history , and now an amazing future secured .

I don't know , but there aren't many shares available here in the UK today .
Yesterday , most of the day I could only get a quote on 8 shares .
Slightly better today at 12 shares max ( £38)
Either my broker is only getting the crumbs , or they are keeping them for a bigger customer .

Nas is up again at 2.94 euro

I watched the LSE interview last night with JW from a few weeks ago .
Trying to catch up , as I am a new investor as of yesterday in at 16p.
Does seem that there is a lot more in addition to even this massive contract going on , with the gas storage , and all the other contacts that they are starting to win .
Looking forward to seeing this develop .
And with the Mcap so low , even though I missed the single figure start , the company still looks very cheap IMO .